Defense counsel in a pharmaceutical case does not wait to receive your chronology.
They build their own. From the same records you have. With a framework designed specifically to dismantle causation before it reaches a jury.
If your medical record review was not built to anticipate that process, you are not preparing for litigation. You are preparing a document that opposing experts are already prepared to take apart.
This is the reality of high-stakes pharmaceutical record review in 2026. The question is not whether your records will be scrutinized. It is whether your review found what the defense is looking for before they did.
How Defense Teams Use Medical Records in Pharmaceutical Litigation
Defense strategy in drug injury cases is not improvised. It follows a documented analytical sequence, and that sequence begins with the plaintiff’s medical history.
The alternative causation sweep. This is the starting point for every defense expert engaged on a pharmaceutical causation case. They review the plaintiff’s full record set specifically for conditions, prior diagnoses, or lifestyle factors that could independently explain the alleged injury. They are not looking for a single prior diagnosis. They are looking for a pattern — anything that creates doubt about whether the drug caused the harm.
The temporal gap argument. Defense experts measure the distance between alleged drug exposure and symptom onset. If that gap is too short or too long relative to the drug’s known mechanism of action, they argue that the timeline doesn’t support biological plausibility. This argument requires precise dates. It fails when the plaintiff’s records are well-organized and the exposure timeline is clearly sourced. It succeeds when dates are approximate, records are incomplete, or the exposure document is missing.
The prescribing record examination. The prescribing physician’s documentation is frequently overlooked in plaintiff record review. Defense experts read it carefully. It may show that the physician was aware of the plaintiff’s risk factors and prescribed accordingly. It may show that the plaintiff was counselled on the drug’s known side effects and consented to the risk. Either finding significantly weakens a failure-to-warn argument.
Label and post-market surveillance cross-reference. Defense teams review the drug’s labeling history alongside the plaintiff’s medical records. If an adverse event was listed in the drug’s known risk profile, and the prescribing physician’s records show awareness of that risk, the failure-to-warn argument becomes harder to sustain. This analysis requires reading the clinical records against the regulatory history simultaneously — not separately.
Secondary reviewer impeachment. When deposition begins, defense counsel will ask your medical expert who reviewed the records, what their clinical background is, whether they reviewed specific documents, and whether they can identify findings by page and line. If the answer to any of those questions is uncertain, the expert’s credibility takes a hit. The quality of the review they worked from is what protects them in that moment.
What Plaintiff Counsel’s Medical Record Review Must Do Differently Because of This
Knowing the defense framework changes the requirements for plaintiff record review.
The alternative causation audit must be completed before deposition prep begins. Not concurrently with it. If you are still discovering prior diagnoses during deposition preparation, the review was too late. The defense will have found those diagnoses weeks earlier. The audit needs to be completed, documented, and delivered to the expert as part of the initial file package.
The prescribing record is not optional. In pharmaceutical litigation, the prescribing physician’s records should be treated as a primary source, not a supporting document. They may contain the best evidence on the defendant’s side — or the best evidence on yours. You need to know which, and you need to know it before your expert forms opinions.
The exposure timeline must stand on its own. Not as a section within the chronology. As a separate, standalone document with its own source citations. Every date in that document — drug start date, dosage adjustment, discontinuation, any re-initiation — must reference a specific record, provider, and page number. This is the document the defense temporal gap argument will be tested against. It must not have approximations.
Clinical records must be read against the label. Reviewers who work in pharmaceutical litigation specifically need to understand the product’s prescribing information, its black box warnings if applicable, and any post-market label changes. A treating physician’s note has different evidentiary value depending on whether the drug’s label addressed the risk being documented. This cross-referencing belongs in the review, not in a separate memo the expert has to prepare.
Page citations are not courtesy. They are litigation armor. Every finding in the review must reference a specific document, provider, and page. When the defense asks your expert where in the records they found a particular fact, the answer must be immediate and precise. Anything less is an opening for impeachment.
The Prescribing Record: The Most Overlooked Document in Pharmaceutical Litigation
In over 25 years of medical-legal record review, prescribing physician records are the documents most frequently absent from plaintiff record requests in pharmaceutical litigation.
This is significant for two reasons.
First, those records may contain favorable evidence. The prescribing physician may have documented a causal connection between the drug and the adverse event. They may have noted a pattern across multiple patients. They may have submitted a MedWatch report. Plaintiff counsel who does not have these records is leaving potentially favorable evidence uncollected.
Second, those records will be obtained by the defense. When they are, and when they contain unfavorable evidence — documented risk disclosure, patient consent, prior medical history that supports alternative causation — plaintiff counsel sees that evidence for the first time in deposition. That is a recoverable situation. It is also an avoidable one.
Request the prescribing physician’s records as part of the initial records request. Review them as a primary document. They belong in the baseline file, not in a supplemental request filed six months into the litigation.
Expert FAQ: Medical Record Review Strategy for Pharmaceutical Litigation
How do defense experts typically use medical records to challenge pharmaceutical litigation causation claims?
Defense experts follow a structured process. They begin with an alternative causation sweep — searching the full record set for conditions, prior diagnoses, or lifestyle factors that could independently explain the plaintiff’s injury. They then examine the temporal relationship between drug exposure and symptom onset, looking for gaps or timing inconsistencies that argue against biological plausibility. Finally, they cross-reference the treating physician’s records against the drug’s labeling history to identify any documented risk disclosures or patient consent. Plaintiff record review that does not anticipate each of these steps will encounter avoidable problems in deposition and at trial.
What is the temporal gap argument in pharmaceutical litigation, and how does record review address it?
The temporal gap argument holds that the timeline between drug exposure and symptom onset does not support the drug’s known mechanism of action, making causation biologically implausible. Defense experts use this argument when the plaintiff’s records do not clearly establish when exposure began, when symptoms first appeared, or both. Plaintiff record review addresses this by building a standalone exposure timeline — a separate document with page-level citations showing drug initiation, dosage changes, discontinuation, and symptom onset dates. That document is what the temporal gap argument is tested against. Without it, the argument is harder to rebut.
Why is the prescribing physician’s record so important in pharmaceutical litigation?
The prescribing physician’s records document the clinical decision to use the drug — what the physician knew about the patient’s risk factors, what risks were disclosed, and what alternatives were considered. In a failure-to-warn case, this is central evidence. It may support the plaintiff’s position if the physician was not adequately informed of the drug’s risks. It may support the defense if the physician was aware of the risks and prescribed anyway. Either way, plaintiff counsel needs to know what those records contain before the case is valued and before experts form opinions.
What does page-level citation mean in a pharmaceutical litigation medical record review, and why does it matter?
Page-level citation means that every finding in the medical record review references a specific document, provider name, and page number in the source records. This matters because in pharmaceutical litigation, every fact in the chronology will eventually be tested. When a defense expert or opposing counsel asks where in the records a particular finding was documented, the answer must be immediate and verifiable. A review that cannot be sourced at the page level cannot be defended at that level — and that is where expert credibility is won or lost.
How should pharmaceutical litigation record review handle records obtained from multiple healthcare systems or countries?
Records from different systems arrive in different formats, terminologies, and organizational structures. The first step is normalization — converting all records into a consistent, navigable format regardless of source. The second step is reconciliation — identifying where records from different systems describe the same events and noting any terminology or diagnostic discrepancies. Those discrepancies matter: a condition documented under one diagnostic code in a US facility and a different term in a European clinical trial is the same condition, and the review must make that connection. Records in languages other than English require certified medical translation before they can be meaningfully reviewed.
What is the right time to engage a medical record review service in a pharmaceutical litigation matter?
At intake, where possible. The earlier the review is completed, the earlier the legal team understands the actual evidentiary landscape. Early review informs case valuation, expert selection, discovery planning, and settlement strategy. Record review completed close to trial is reactive. It answers questions the defense is already prepared for. Early review is strategic. It shapes the questions before the defense has framed them.
CUBEXLE: Pharmaceutical Litigation Medical Record Review
CUBEXLE’s pharmaceutical litigation teams have conducted medical record review for plaintiff and defense counsel across drug injury cases, mass tort matters, and product liability proceedings for over 25 years.
We build every review to function as litigation intelligence — not just documentation. That means page-level citation throughout, standalone exposure timelines, pre-existing condition audits completed before expert engagement, and prescribing record analysis as a standard component.
Every review is quality-checked by a credentialed medical professional before delivery. HIPAA-compliant, ISO 27001-certified, SOC-compliant.